Obesity startup Obalon pulls in $1.5M

We haven't heard much from Obalon Therapeutics in a while. The obesity treatment device startup last drew attention in 2008, when it had announced raising $4.7 million of a $7.7 million first round of funding, right about when it launched.  And then: virtually nothing since.

Until now: Obalon has raised another $1.5 million from two unnamed investors to continue its work, according to its SEC filing. MedCity News offers a solid account of the funding, also pointing out that the company has been in stealth mode for a while.

Obalon alternately describes its technology as a gastric balloon and "a novel gastric space occupying device," according to Clinicaltrials.gov, which holds some news on the company's clinical trials so far. According to the website, Obalon completed a 60-day pilot study of its product last fall that evaluated safety and efficacy, and is holding an ongoing non-randomized observational study. Both trials involved subjects in Mexico.

As MedCity News points out, newer obesity treatment companies including GI Dynamics and EnteroMedics are emerging, with development of devices that block absorption of food or create an artificial sense of fullness, among other areas. They'd compete with Allergan's Lap-Band, which drew fire from Consumer Reports in recent days: The consumer publication claims that it is among many devices on the market that haven't been properly tested for safety.

- here's the MedCity News story
- read the SEC filing
- consider Obalon's clinical trial info

Special Report: GI Dynamics - Top 10 VC deals, H2 2011

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.